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Methods for preliminary determination of pemetrexed in
macromolecular drug-carrier systems
Pemetrexed (PMX) is an antifolate drug utilized in the 
treatment of non-small cell lung cancer. For studies of po-
tential macromolecular carriers for PMX, fast and precise 
methods were developed to determine the bound and free 
drug contained in investigated conjugate preparations. The 
analysis of the total amount of PMX in conjugates was 
based on absorption spectrophotometry. The linearity was 
found in the range of 4.697–46.97 μmol L–1 PMX. The limit of 
quantitation was 1.070 μmol L–1. The method for the analy-
sis of unbound PMX was based on size-exclusion chroma-
tography and detection at 225 nm. This method shows lin-
ear range of 2.230–223.0 μmol L–1. LOQ was 0.539 μmol L–1. 
The proposed methods can be used both for the character-
ization of the polysaccharide based conjugates of PMX and 
for the determination of conjugate drug release profi les.
Keywords: pemetrexed, macromolecular drug-carrier, size-
exclusion chromatography, ultraviolet spectroscopy
The search for new, innovative methods of disease treatment, especially for cancer, is 
an ongoing challenge in both industry and academia. Conjugates composed of high mo-
lecular mass natural or synthetic polymers and antineoplastic agents may exhibit a range 
of positive features, such as increased half-life in an organism, increased stability, reduced 
immunogenicity and intensifi ed therapeutic effi cacy (1, 2). The combination of drugs already 
used in therapy with high molecular carriers may lead to a new therapeutic quality (3).
Pemetrexed (PMX) is a multi-target antifolate. It is an antimetabolite of folic acid and 
the mechanism of its action is based on its ability to inhibit the activity of the enzymes 
involved in purine and pyrimidine synthesis: thymidylate synthase (TS), dihydrofolate 
reductase (DHFR), and glycinamideribonucleotideformyl transferase (GARFT) (4). Aft er 
being transported into the cell via the reduced folate carrier or/and folate receptors, PMX 
is polyglutamated to the active pentaglutamide by a reaction catalyzed by polylpolygluta-
mate synthase (5). PMX has a wide usage in the treatment of pleural mesothelioma (6), 
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range of disadvantages characteristic of low molecular compounds, such as fast metabo-
lism and fast excretion from the organism, as well as adverse biodistribution and low se-
lectivity of therapeutic use (9). Moreover, its clinical use is limited by dose-dependent 
toxicity. Solving these problems involves the coupling of PMX with macromolecular car-
riers, resulting in enhancement of the delivery and selectivity and improvement of the 
pharmacological properties of PMX.
There have been numerous scientifi c reports concerning another antifolate drug – 
methotrexate (MTX) – conjugated with a polysaccharide based, high molecular mass car-
rier such as mannan (10), dextranes (11), hyaluronic acid (12) or hydroxyethyl starch (HES) 
(13). In vivo studies have indicated that methotrexate conjugated with HES [a modifi ed 
polymer, based on amylopectin, used clinically as a colloidal plasma volume expander 
(14)] exhibits high effi  cacy for the treatment of experimental tumors. Studies of HES as a 
carrier for MTX, conducted in our laboratory, are currently being extended by experiments 
with PMX covalently bound (ester bond) with HES. In order to investigate the potential of 
HES-PMX conjugates, a fast and precise method is needed to determine the total and free 
drug contained in investigated conjugate preparations.
The aim of this study was to develop novel methods for the determination of PMX in 




The pemetrexed standard was purchased from Eli Lilly (USA). Sodium bicarbonate, 
analytical grade, was obtained from Avantor Performance Materials (Poland). HES-PMX 
conjugates were obtained according to the previously described methods (11, 13). The wa-
ter used was produced by a Direct-Q3 UV system (Millipore, USA).
PMX standard preparations. – Diff erent concentrations of PMX were prepared by dilut-
ing the stock solution of PMX (58.55 mmol L–1) in 0.1 mol L–1 sodium bicarbonate.
Ultraviolet spectroscopy (UV)
All measurements were conducted on a Specord® 250 (Analytic Jena, Germany) spec-
trophotometer at ambient temperature. UV spectra were recorded in the range 210–350 
nm, with a slit width of 1 nm and scan speed of 50 nm s–1. Quartz cells with 1-cm light path 
length were used for measurements. Samples were prepared in sodium bicarbonate solu-
tion (0.1 mol L–1).
Size-exclusion chromatography
Ultimate 3000 HPLC system (Dionex, USA) was used equipped with a DAD detector 
connected to a Superdex® 30 Peptide (GE Healthcare, UK) column (4.6 × 150 mm, 34 μm) at 
22 °C. Sodium bicarbonate solution (0.1 mol L–1) was used as the mobile phase at a fl ow rate 
of 0.4 mL min–1. UV detection was done at 225 nm; injection volume was 10 μL. It was 
validated according to the following parameters.
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Specifi city. – Specifi city was determined by analyzing the chromatograms of hydroxy-
ethyl starch in comparison with the chromatogram of a mixture of hydroxyethyl starch 
and pemetrexed to confi rm that none of the excipients interfered with quantitation of the 
drug.
Linearity and range. – Linearity of the methods was determined by measuring indepen-
dent concentrations of the calibration standards of PMX.
The linearity of the method for the analysis of total PMX in preparations was deter-
mined by measuring fourteen independent concentrations (μmol L–1) of the calibration 
standards (4.679; 7.019; 9.359; 11.70; 14.04; 16.38; 18.72; 21.06; 23.40; 28.08; 32.76; 37.43; 42.11; 
46.79). Each concentration was measured at 225 nm and absorbance was plott ed vs. concen-
tration; regression parameters were evaluated. The linearity of the method for the analysis 
of unbound PMX in preparations was determined by the measurement of 11 independent 
concentrations (μmol L–1) of the calibration standards (2.230; 4.461; 8.622; 13.38; 17.84; 22.30; 
44.61; 89.22; 133.8; 178.4; 223.0). The calibration curve of the peak area vs. concentration was 
plott ed and regression parameters were determined.
Accuracy. – In order to evaluate this parameter, three independent replicates of each 
sample (mixture of hydroxyethyl starch and pemetrexed) were measured and then com-
pared to the theoretical concentration of PMX in the sample, with data calculated from the 
calibration curve. The result was presented as the percentage of recovery.
Precision. – Precision of the method was calculated by comparing the results for trip-
licates of one sample (mixture of hydroxyethyl starch and pemetrexed). The result was 
presented as RSD.
Limit of detection (LOD) and limit of quantitation (LOQ). – LOD was calculated based on 
a signal to noise ratio of 3:1 and LOQ based on a signal to noise ratio of 10:1.
Robustness. – Robustness was evaluated by analyzing the drug concentration (116.9 
μmol L–1) with variations in the temperature of the analytical column (15 and 35 °C), pH 
of the mobile phase (7.2 and 7.85) and fl ow rate (0.38 and 0.42 mL min–1). Samples (mixture 
of hydroxyethyl starch and pemetrexed) were determined in triplicate for each variation 
of the method conditions. Results were compared with the previously reported results.
Determination of pemetrexed in HES-PMX conjugates
The conjugate was dissolved in NaHCO3 (0.1 mol L–1) and the total PMX was mea-
sured by the spectrophotometric method. Based on this result, the conjugate was diluted 
with NaHCO3 0.1 mol L–1 to a fi nal concentration of 223.0 μmol L–1 (total PMX) and ana-
lyzed for unbound PMX by the gel chromatographic method. In addition, a quantitative 
analysis of the PMX released from the HES-PMX conjugate was performed. The conjugate 
was completely hydrolyzed in NaOH (0.1 mol L–1) for 24 hours and then analyzed for un-
bound PMX by the chromatographic method. Total glucose contents in HES-PMX prepara-
tions were determined using the phenol-sulfuric acid method (15).
Analysis of the HES-PMX conjugate with PMX standard addition
The conjugate and PMX standard were diluted in NaHCO3 (0.1 mol L–1) to a fi nal con-
centration of 339.9 μmol L–1 (total PMX 116.9 μmol L–1 was PMX standard) before chromato-
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graphic analysis of unbound PMX in preparations. The drug content determined accord-
ing to the method were reduced by the amount of free drug in the HES-PMX conjugate, 
and then the statistical signifi cance was determined by Student’s t-test.
RESULTS AND DISCUSSION
The analysis of total PMX in preparations was based on absorption spectrophotome-
try in 0.1 mol L–1 sodium bicarbonate at  = 225 nm. Results of the validation of the method 
are presented in Table I. The method showed linearity in a concentration range of 4.679–
46.79 μmol L–1 with a coeffi  cient of determination of 0.9993. The accuracy of the method, 
expressed as a percentage of recovery, was found to be 96.2–101.7 %. Precision of the method, 
expressed as RSD, was found to be 0.9–5.5 %. LOD and LOQ of the method were found to 
be 0.3530 and 1.070 μmol L–1, respectively.
Unbound PMX in preparations was determined by size-exclusion chromatography. 
Results of the validation of the method are presented in Table I. The results of specifi city 
showed that there was no interference at the retention time of the drug from a mixture of 
hydroxyethyl starch and PMX (Figs. 1a and b). Moreover, the photodiode array detector 
indicated that the PMX peak was free from interference (purity index > 0.9999). Linearity 
concentration range was 2.230–223.0 μmol L–1 with a coeffi  cient of determination of 0.9999. 
Accuracy of the method, expressed as recovery, was found to be 95.4–105.6 %. RSD was 
found to be 0.1–1.0 %. LOD and LOQ were found to be 0.1616 and 0.5386 μmol L–1, respec-
tively. Robustness was based on RSD values obtained by changing analytical parameters 
such as the analytical column temperature (15 and 35 °C), pH of the mobile phase (7.2 and 
7.85) and fl ow rate (0.38 and 0.42 mL min–1). The method was considered robust because 
the RSD values were lower than 0.9 %, as summarized in Table II. As expected, some 
variation in the retention time was observed, without compromising the drug content 
determination. The use of the standard addition method confi rmed confi dence interval of 
the added standard CI95 (116.3; 118.1; p = 0.8597).
Table I. Validation parameters for the analysis of PMX in macromolecular drug-carrier systems 
Parameter The method for theanalysis of total PMX
The method for the
analysis of unbound PMX
Linearity (μmol L–1) 4.679–46.79 2.230–223.0
Slope (mean ± SD) 0.02934 ± 0.00012 0.6874 ± 0.0009
Intercept (mean ± SD) 0.03834 ± 0.00314 –0.4432 ± 0.0901
Coeffi  cient of determination (R2) 0.9993 0.9999
Precision (RSD, %) 0.9–5.5 0.1–1.0
Accuracy (recovery, %) 96.2–101.7 95.4–105.6 
LOD (μmol L–1) 0.3530 0.1616 
LOQ (μmol L–1) 1.070 0.5386 
PMX retention time (min) – 8.887 ± 0.012 min
Molar absorptivity (ε, L mol–1) 29300 cm–1 –
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New methods have been used to determine both the overall and the covalently bound 
PMX in the HES-PMX conjugate. The conjugate contained 44.6 × 10–3 covalently bound 
PMX residued per anhydroglucose unit and there was 0.7 % of free (unbound) PMX in the 
fi nal preparations (Table III, Figs. 2a and b). In addition, consistent results were obtained 
for the quantitative analysis of total PMX (aft er complete release from the HES-PMX con-
Table II. Robustness data for pemetrexed analysisa









































Fig. 1. HPLC chromatograms ( = 225 nm) obtained for: a) hydroxyethyl starch and b) mixture of 
hydroxyethyl starch and PMX.
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jugate) via size-exclusion chromatography and for the analysis of total PMX via absorption 
spectrophotometry (Table III). The diff erence between these measurements did not exceed 
1 % PMX (below RSD of both methods).
CONCLUSIONS
The proposed methods can be used both for the characterization of the polysaccha-
ride based conjugates of PMX and for the determination of conjugate drug release profi les.
Acknowledgments. – This project was supported by the National Science Centre, Poland (N N302 
098434).
Fig. 2. a) Analytical size-exclusion chromatogram of HES-PMX conjugate, b) UV spectrum of HES-
PMX conjugate.
Table III. HES-PMX conjugate characterization (fi nal preparation)a
Parameter PMX found 
Total PMX (bound and unbound)b 8.914 μmol L–1
Total PMX (aft er releasing from conjugate)c 8.997 μmol L–1
Free PMX (unbound)d 0.06592 μmol L–1
HES (glucose equivalent)e 198.3 μmol L–1
SLf 0.0446
a For details see the experimental section.
b Total PMX content in the fi nal preparation of HES-PMX conjugate, determined by UV spectrophotometry.
c Total PMX completely released from HES-PMX conjugate, determined by SEC.
d Free (unbound) PMX in the fi nal preparation of HES-PMX conjugate, determined by SEC.
e Total glucose in HES-PMX preparation, determined by the phenol-sulfuric acid method.
f SL – molar substitution level by PMX on glucose units.
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